AMG 757 Studie A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer (Aktiv)
Erstlinie
AMG 20200469 A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (Aktiv)
CAAA601A42101 Phase-Ib-Studie zu [177Lu]Lu-DOTA-TATE bei Patienten mit kleinzelligem Lungenkrebs im fortgeschrittenen Stadium (Aktiv)
CRISP Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (Aktiv)
Dolphin A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in patients with local limited small cell lung cancer (Aktiv)
TREASURE Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease (Aktiv)
Zweitlinie oder später
20210004 A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (Aktiv)
BI 1438-0002 A Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 764532 combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3. (Aktiv)
BI 1438-0009/ DAREON-9 DAREON-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With Topotecan for the Treatment of Patients With Small Cell Lung Cancer (Aktiv)
BMS CA 209-331 (NIVO SCLC (331)) Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer (CheckMate331) (Aktiv)
DLL3 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). (Aktiv)
DeLLphi-305 20200041 A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) (Aktiv)
DeLLphi-306 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306) (Aktiv)
PM1183-C-008-21 A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial) (Aktiv)
SORATRAM Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)